Work

A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Year: 2025

Type: article

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.mct-24-1015

Authors: Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, Amanda L. McCormick, Trevor S. Anderson, Savanna L. Smith, Caryn Lawrence, Duke Appiah, Devin B. Lowe

Institutions: Texas Tech University Health Sciences Center, Texas Tech University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Cancer Prevention and Research Institute of Texas

Award: Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC

OpenAlex ID: W4409294750

FWCI: 1.081

Cites: 57

Cited by: 3

Related to: 10